On this episode of Managed Care Cast, we speak with the lead clinician of a study by the Epic Health Research Network and Kaiser Family Foundation, which found that routine medical care and hospital admissions remained below expected levels in the early months of 2021, marking the second consecutive year for such results.
As health care utilization experienced marked declines in 2020 due to COVID-19, there were hopeful expectations from the medical community that routine care would rebound or even increase in 2021 to make up for the pandemic.
However, according to a recent study by the Epic Health Research Network and Kaiser Family Foundation, findings indicate that routine medical care and hospital admissions remained below expected levels in the early months of 2021, marking the second consecutive year for such results.
On this episode of Managed Care Cast, we speak with Jackie Gerhart, MD, family medicine physician at Epic and lead clinician on the study, who addressed several potential implicating factors of the study findings and the adverse impact that continued forgone medical care may have on public health in the near future.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More